Covidien has signed a definitive agreement to acquire all outstanding capital stock of Barrx Medical for around $325m.

The acquisition will expand Covidien’s ability to treat Barrett’s oesophagus by giving it access to Barrx’s bipolar radiofrequency ablation devices.

Barrx’s Halo(90), Halo(90) Ultra and Halo(360+) ablation catheters remove diseased tissue and allow normal cells to regrow.

Barrx Medical president and CEO Greg Barrett said that the company expects the acquisition to enable the clinical trial evaluation of the Halo system in other portions of the gastrointestinal tract as well.

Upon completion of transaction, Covidien will include Barrx Medical business in its Energy product line in the medical devices segment.

The transaction, subject to customary closing conditions and certain regulatory approvals, is likely to close by the end of January 2012.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.